Literature DB >> 10927799

Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis.

S J Khoury1, C R Guttmann, E J Orav, R Kikinis, F A Jolesz, H L Weiner.   

Abstract

OBJECTIVE: To determine whether changes in activation markers on peripheral blood T cells correlate with disease activity in patients with multiple sclerosis.
DESIGN: In a prospective longitudinal study during 1 year, we analyzed the change in percentage of activated T lymphocytes in the peripheral blood of 40 patients with multiple sclerosis in relation to clinical findings and changes on brain magnetic resonance imaging (MRI) scans. The patients underwent repeated imaging of the brain (mean number of MRIs for each patient, 22) at the time blood samples were obtained as well as at monthly neurological examinations, and at the time of scoring on the Kurtzke Expanded Disability Status Scale (EDSS) and ambulation index scale.
RESULTS: A change in the percentage of cells expressing the activation markers interleukin 2 receptor (CD25), class II major histocompatibility complex (MHC) (I3) or surface dipeptidyl peptidase (CD26) correlated significantly with a change in lesion volume or a change in number of gadolinium-enhancing lesions as detected on MRI. Changes in CD25( +) cells and in CD4(+) cells expressing class II MHC also correlated with changes in disability as measured by EDSS in patients with relapsing-remitting disease, and changes in CD4(+)CD25(+) cells correlated with the occurrence of attacks in patients with relapsing-remitting disease. These correlations are dependent on measurement of changes between time points sampled at 1- or 2-week intervals.
CONCLUSION: There is a linkage between peripheral T-lymphocyte activation as measured by cell surface markers and disease activity in patients with multiple sclerosis. Arch Neurol. 2000;57:1183-1189

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10927799     DOI: 10.1001/archneur.57.8.1183

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  27 in total

Review 1.  T cells, cytokines, and autoantigens in multiple sclerosis.

Authors:  B Gran; A Rostami
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 2.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

3.  PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.

Authors:  Lindsay M Webb; Stephanie A Amici; Kyle A Jablonski; Himanshu Savardekar; Amanda R Panfil; Linsen Li; Wei Zhou; Kevin Peine; Vrajesh Karkhanis; Eric M Bachelder; Kristy M Ainslie; Patrick L Green; Chenglong Li; Robert A Baiocchi; Mireia Guerau-de-Arellano
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

4.  Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis.

Authors:  Makoto Matsui; Shin-ichi Araya; Hui-Yun Wang; Kouji Matsushima; Takahiko Saida
Journal:  J Neurol       Date:  2005-03-21       Impact factor: 4.849

5.  Soluble CD26 and CD30 levels in CSF and sera of patients with relapsing neuromyelitis optica.

Authors:  Koichi Narikawa; Tatsuro Misu; Kazuo Fujihara; Ichiro Nakashima; Shigeru Sato; Yasuto Itoyama
Journal:  J Neurol       Date:  2005-07-18       Impact factor: 4.849

6.  Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study.

Authors:  Khalaf Kridin; Kyle Amber; Mogher Khamaisi; Doron Comaneshter; Erez Batat; Arnon D Cohen
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

7.  Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis.

Authors:  Anne I Boullerne; Jose J Rodriguez; Tarik Touil; Bruno Brochet; Stephan Schmidt; Nora D Abrous; Michel Le Moal; Jeffrey R Pua; Mark A Jensen; Willy Mayo; Barry G W Arnason; Klaus G Petry
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

8.  Central inflammation versus peripheral regulation in multiple sclerosis.

Authors:  L J Edwards; B Sharrack; A Ismail; H Tumani; C S Constantinescu
Journal:  J Neurol       Date:  2011-03-09       Impact factor: 4.849

Review 9.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

10.  The type of responder T-cell has a significant impact in a human in vitro suppression assay.

Authors:  Srikanta Jana; Hope Campbell; Jeffrey Woodliff; Jill Waukau; Parthav Jailwala; Jugal Ghorai; Soumitra Ghosh; Sanja Glisic
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.